Furthermore, given the possible distal effects of T cells, comparison between Dok-3 expression in peripheral CD4+ and CD8+ T cells from adenocarcinoma-bearing patients and that from non–adenocarcinoma-bearing patients with familial adenomatous polyposis might help to gain insight into the clinical relevance of Dok-3 loss–induced malignant progression, even though such datasets appear unavailable at this point. The gene discussed is CD4; the disease is adenocarcinoma.